Lichen Nitidus Treatment Market - Global Forecast Till 2023

Report / Search Code: MRFR/HC/2896-HCRR  
Publish Date: May, 2018

Price

<table>
<thead>
<tr>
<th>Description:</th>
</tr>
</thead>
<tbody>
<tr>
<td>Lichen Nitidus Treatment Market Information: By Type (Topical, Oral), By Treatment (Corticosteroids, Retinoid, Antihistamines, Phototherapy, Others), By End Users (Hospitals, Dermatology Clinics, Others) - Global Forecast Till 2023</td>
</tr>
</tbody>
</table>

Figure 1 Global Lichen Nitidus Treatment Market by type, 2016 (%)

**Intended Audience**

- Medical Device Manufacturers
- Medical Device Suppliers
- Medical Research Laboratories
- Research and Development (R&D) Companies
- Market Research and Consulting Service Providers
- Potential Investors

**Research Methodology**


**Market Synopsis of the Global Lichen Nitidus Treatment Market**

**Market Scenario**

Lichen nitidus is a rare, chronic skin disease characterized by flat-topped, and skin-colored micropapules. Characteristics of these micropapules are the size, shape (pin point), color, location and itching. It mostly affects geriatric and pediatric population. They commonly occur on the chest, abdomen, arms and genital areas, including the penis. In this disease, T lymphocytes get activated resulting in the formation of these micropapules. In lichen nitidus,
linear arrangement of micropapules can be seen on the fore arm or affected area.

Increasing prevalence of skin diseases across the globe is the major factor contributing the growth of the market. Unawareness about rare skin diseases among people may act as a restrain for the market growth.

The global lichen nitidus treatment market is expected to grow at a CAGR of 8.7% during the forecast period and is estimated to reach USD 170 million by 2023.

**Segments**
The global lichen nitidus treatment market is segmented on the basis of types, which includes oral and topical treatment. On the basis of treatment, the market is segmented into corticosteroids, retinoid, antihistamines, phototherapy and other treatment. On the basis of end user, the market is segmented into hospitals, dermatology clinics, and others.

**Regional Analysis of the Global Lichen Nitidus Treatment Market**
The Americas accounts for the largest share of the global lichen nitidus treatment market due to increasing prevalence of skin disease, availability of treatment methods at affordable cost and demand for new topical products for its treatment. According to the American Osteopathic College of Dermatology, the number of people suffering from lichen nitidus is increasing at a steady rate in American countries. It also stated that in 2013, USD 75 billion were spent on the treatment of various skin diseases. Aging population is another factor responsible for the market growth in these countries.

Europe is the second largest market that holds a noticeable share of the global lichen nitidus treatment market owing to an increase in the awareness regarding skin diseases, demand for skin care cosmetics, and growing market for dermatology in many European countries.

In Asia Pacific, the market is driven by increasing in number of dermatology clinics, rising demand for evidence based skin care and increasing prevalence of diseases associated with lichen nitidus such as atopic dermatitis and tuberculosis.

The Middle East & Africa is expected to show a steady but positive growth in this market due constant demand for diagnostics services in dermatology, rising awareness about lichen nitidus among children and its prevention.
Key Players in the Global Lichen nitidus treatment Market

Some of the key players in this market are Pfizer Inc. (U.S), Novartis AG (Switzerland), Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc. (U.S), Sanofi (France), GlaxoSmithKline plc. (U.K), AstraZeneca (U.K), Hubei Gedian Humanwell Pharmaceutical Co.,Ltd (China), Farmabios SPA (Italy), Horizon Pharma plc. (Ireland).

The report on the global lichen nitidus treatment market of Market Research Future comprises of extensive primary research along with the detailed analysis of qualitative as well as quantitative aspects by various industry experts, key opinion leaders to gain deeper insight to the market and industry performance. The report gives a clear picture of the current market scenario which includes historical and projected market size in terms of value and volume, technological advancement, macro economical and governing factors in the market. The report provides details information and strategies of the top key players in the industry. The report also gives a broad study of the different market segments and regions.
4.4 Challenges
4.5 Macroeconomic Indicators
4.6 Technology Trends & Assessment

5. Market Factor Analysis
5.1 Porters five Forces Analysis
5.1.1 Bargaining Power of Suppliers
5.1.2 Bargaining Power of Buyers
5.1.3 Threat of New Entrants
5.1.4 Threat of Substitutes
5.1.5 Intensity of Rivalry
5.2 Value Chain
5.3 Investment Feasibility Analysis
5.4 Price Factor Analysis

6 Global Lichen Nitidus Treatment Market, by Type
6.1 Introduction
6.2 Topical
6.3 Oral

7 Global Lichen Nitidus Treatment Market, by Treatment
7.1 Introduction
7.2 Corticosteroids
7.3 Retinoid
7.4 Antihistamines
7.5 Others

8 Global Lichen Nitidus Treatment Market, by End User
8.1 Introduction
8.2 Hospitals
8.3 Dermatology Clinics
8.4 Others

9 Global Lichen Nitidus Treatment Market by Region
9.1 Introduction
9.2 Americas
9.2.1 North America
9.2.1.1 US
9.2.1.2 Canada
9.2.2 Latin America
9.3 Europe
9.3.1 Western Europe
9.3.1.1 Germany
9.3.1.2 France
9.3.1.3 UK
9.3.1.4 Italy
9.3.1.5 Spain
9.3.1.6 Rest of Western Europe
9.3.2 Eastern Europe
9.4 Asia Pacific
9.4.1 Japan
9.4.2 China
9.4.3 India
9.4.4 Republic of Korea
9.4.5 Australia
9.4.6 Rest of Asia Pacific
9.5 Middle East & Africa
9.5.1 United Arab Emirates
9.5.2 Saudi Arabia
9.5.3 Oman
9.5.4 Kuwait
9.5.5 Qatar
9.5.6 Rest of Middle East & Africa

10 Company Landscape

10.1 Introduction
10.2 Market share Analysis
10.3 Key Development & Strategies
10.3.1 Key Developments
11 Company Profiles

11.1 Pfizer Inc.
  11.1.1 Company Overview
  11.1.2 Product Overview
  11.1.3 Financials
  11.1.4 SWOT Analysis

11.2 Novartis AG
  11.2.1 Company Overview
  11.2.2 Product Overview
  11.2.3 Financial Overview
  11.2.4 Key Developments
  11.2.5 SWOT Analysis

11.3 Merck Sharp & Dohme Corp.
  11.3.1 Company Overview
  11.3.2 Product Overview
  11.3.3 Financial Overview
  11.3.4 Key Development
  11.3.5 SWOT Analysis

11.4 Sanofi
  11.4.1 Company Overview
  11.4.2 Product/Business Segment Overview
  11.4.3 Financial Overview
  11.4.4 Key Development
  11.4.5 SWOT Analysis

11.5 GlaxoSmithKline plc.
  11.5.1 Company Overview
  11.5.2 Product Overview
  11.5.3 Financial overview
  11.5.4 Key Developments

11.6 AstraZeneca
  11.6.1 Company Overview
  11.6.2 Product Overview
11.6.3 Financial Overview

11.6.4 Key Developments

11.7 Hubei Gedian Humanwell Pharmaceutical Co. Ltd.

11.7.1 Overview

11.7.2 Product Overview

11.7.3 Financials

11.7.4 Key Developments

11.7.5 SWOT Analysis

12 MRFR Conclusion

12.1 Key Findings

12.1.1 From CEO's View Point

12.1.2 Unmet Needs of the Market

12.2 Key Companies to Watch

12.3 Prediction of Healthcare Industry

13 Appendix